Stock Comparison

RNA vs SRPT

RNA vs Sarepta Therapeutics Inc

The Verdict

RNA takes this one.

Winner

RNA

8.0

out of 10

Hidden Gem

SRPT

Sarepta Therapeutics Inc

6.8

out of 10

Solid Pick

Head-to-Head

$10.8B

Market Cap

$1.9B

N/A

P/E Ratio

29.0

N/A

Profit Margin

3.0%

N/A

Return on Equity

4.9%

N/A

Debt-to-Equity

0.7

Aggressive

Overall Risk

Moderate

8.0

DVR Score

6.8

The Deep Dive

RNA8.0/10

Avidity Biosciences (RNA) continues to demonstrate strong 10x growth potential, sustained by its proprietary Antibody Oligonucleotide Conjugate (AOC) platform. The lead asset, AOC 1001 for Myotonic Dystrophy Type 1 (DM1), remains critically important, with the path to potential regulatory filing in late 2026/early 2027 still intact. This timeline, coupled with ongoing clinical progress for AOC 102...

Full RNA Analysis

SRPT6.8/10

Score Change Explanation: The previous analysis (2026-04-05) highlighted "persistent commercial execution issues for Elevidys, reflected in Q4 2025's wider-than-expected loss and reduced 2026 revenue guidance." The Q1 2026 earnings, reported on May 6, 2026, represent a material positive change. Sarepta reported a significant swing to GAAP operating income of $358.4 million and GAAP net income of $...

Full SRPT Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.